Abstract
In a double-blind trial, 12 patients with probable Alzheimer's disease were treated for 6 weeks with placebo and 6 weeks with monosialoganglioside (GM1) (100 mg/day i.m.), which potentiates the actions of nerve growth factor. GM1 failed to produce significant improvement in patients' cognitive test performance, suggesting that this is not a viable approach to the treatment of cognitive deterioration in Alzheimer's disease.
Original language | English |
---|---|
Pages (from-to) | 126-129 |
Number of pages | 4 |
Journal | American Journal of Psychiatry |
Volume | 151 |
Issue number | 1 |
DOIs | |
State | Published - Jan 1994 |
Externally published | Yes |